StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Equities researchers at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a report issued on Saturday. The firm set a "sell" rating on the stock.

Separately, Piper Sandler reissued an "overweight" rating and issued a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Performance

NYSE:NSPR remained flat at $2.48 on Friday. The company's stock had a trading volume of 68,659 shares, compared to its average volume of 23,104. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.67. The stock's fifty day moving average price is $2.65 and its 200-day moving average price is $2.56. The stock has a market cap of $61.83 million, a price-to-earnings ratio of -3.35 and a beta of 0.93.

InspireMD (NYSE:NSPR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The company had revenue of $1.74 million during the quarter, compared to the consensus estimate of $1.74 million. During the same period in the prior year, the firm posted ($0.24) earnings per share. As a group, equities research analysts forecast that InspireMD will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 183,746 shares of the company's stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.